000403 派林生物
按盤價 
8.990 -0.210 (-2.283%)
8.990 -0.210 (-2.283%) | 2026/09 - 九個月 | 2025/12 | 2024/12 | 2023/12 | 2022/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | 1.873 | 5.237 | 9.709 | 8.563 | 8.901 |
| 總資產報酬率 ROA (%) | 1.571 | 4.481 | 8.338 | 7.369 | 7.792 |
| 投入資產回報率 ROIC (%) | 1.674 | 4.782 | 8.974 | 7.999 | 8.489 | 邊際利潤分析 |
| 銷售毛利率 (%) | 32.194 | 41.534 | 49.132 | 51.481 | 52.127 |
| 營業利潤率 (%) | 13.012 | 20.026 | 33.161 | 29.853 | 27.583 |
| 息稅前利潤/營業總收入 (%) | 11.169 | 17.634 | 30.271 | 27.077 | 25.157 |
| 淨利潤/營業總收入 (%) | 10.802 | 15.936 | 28.065 | 26.258 | 24.434 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 93.979 | 122.561 | 98.379 | 100.163 | 98.707 |
| 價值變動淨收益/利潤總額(%) | 2.788 | 2.648 | 2.828 | -1.681 | 1.206 |
| 營業外收支淨額/利潤總額(%) | -4.779 | -5.379 | -3.229 | -1.029 | -0.460 | 償債能力分析 |
| 流動比率 (X) | 2.932 | 3.297 | 3.740 | 3.715 | 3.176 |
| 速動比率 (X) | 1.433 | 1.912 | 2.451 | 2.729 | 2.526 |
| 資產負債率 (%) | 17.702 | 14.632 | 14.371 | 14.004 | 14.046 |
| 帶息債務/全部投入資本 (%) | 11.020 | 8.644 | 7.190 | 5.987 | 4.511 |
| 股東權益/帶息債務 (%) | 799.331 | 1,048.789 | 1,279.664 | 1,551.423 | 2,083.639 |
| 股東權益/負債合計 (%) | 465.239 | 583.931 | 596.391 | 614.644 | 612.517 |
| 利息保障倍數 (X) | -8.937 | -12.868 | -16.344 | -10.952 | -10.939 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 155.351 | 106.717 | 82.369 | 109.718 | 102.622 |
| 存貨周轉天數 (天) | 495.195 | 327.066 | 285.599 | 244.231 | 213.018 |
| 備註： | 報價延遲最少15分鐘，資料更新時間為 13/11/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
